Additional benefit seen for mental health and well-being
Findings show higher risk for nonclearing vitreous hemorrhage, retinal tear and detachment, anterior vitrectomy, and glaucoma surgery
Significant treatment benefits seen at 18 months; in addition, risk for experiencing subsequent end points lower with valacyclovir
Risk for ischemic heart disease elevated even at exposure levels below the current regulatory limit of 10 µg/L
Highest rates of SCD seen for patients with schizophrenic disease; 10-year excess loss of life expected for 18-year-olds with psychiatric disorder
Vyloy is the first and only CLDN18.2-targeted therapy approved in the United States
Significant differences seen in four of six self-reported cognitive function outcomes favoring aerobic exercise initiated with chemo
Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for treatment of motor fluctuations
Similar average advanced colorectal neoplasia per colonoscopy seen with CADe-enhanced and conventional colonoscopy
The most socioeconomically deprived recipients show inferior survival at three and five years after transplantation
Calculator provides individualized recommendations based on risk and complexity factors